Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Pediarix Administered at Birth
NCT00133445Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2005
- Primary completion
- Aug 2006
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) in diphtheria, Tetanus, pertussis, hepatitis B (HBV), poliomyelitis, sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2005; status: completed.
02
Drugs
Bordetella pertussis toxoid antigen (glutaraldehyde inactivated)
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT00133445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133445.